Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 12, 2025 07:00 ET | Source: Lexeo Therapeutics

Lexeo Therapeutics Reports First Quarter 2025 Financial Results and Operational Highlights

Lexeo Therapeutics Reports First Quarter 2025 Financial Results and Operational Highlights
April 07, 2025 06:00 ET | Source: Lexeo Therapeutics

Lexeo Therapeutics Announces Positive Interim Phase 1/2 Data for LX2006 in Friedreich Ataxia Cardiomyopathy Supporting Advancement to Registrational Study

Lexeo Therapeutics Announces Positive Interim Phase 1/2 Data for LX2006 in Friedreich Ataxia Cardiomyopathy Supporting Advancement to Registrational Study
March 24, 2025 07:00 ET | Source: Lexeo Therapeutics

Lexeo Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights

Lexeo Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights
November 13, 2024 07:30 ET | Source: Lexeo Therapeutics

Lexeo Therapeutics Provides Update on Cardiac Portfolio and Reports Third Quarter 2024 Financial Results

Lexeo Therapeutics Provides Update on Cardiac Portfolio and Reports Third Quarter 2024 Financial Results
January 09, 2020 10:24 ET | Source: Retrotope

Retrotope Expands its Drug Pipeline with the First Dosing of RT001 in patients with Friedreich’s ataxia (FA)

LOS ALTOS, Calif., Jan. 09, 2020 (GLOBE NEWSWIRE) -- Retrotope announced today that it has dosed its first patient in a Phase 2/3 clinical trial of RT001 in Friedreich’s ataxia, the most common of...
July 19, 2019 11:15 ET | Source: Retrotope

Retrotope Announces Completion of Series C Preferred Financing and Addition of a Lead Investor on the Board of Directors

LOS ALTOS, Calif., July 19, 2019 (GLOBE NEWSWIRE) -- Retrotope announced today that it closed a Series C financing, enabling expansion of its pipeline of novel first-in-class drugs called D-PUFAs...
May 06, 2019 12:57 ET | Source: Retrotope

Retrotope Announces RT001 Clinical Data Presentation at the 2019 American Academy of Neurology (AAN) Annual Meeting

LOS ALTOS, Calif., May 06, 2019 (GLOBE NEWSWIRE) -- Retrotope announced today positive findings from an expanded access study of the company’s lead candidate, RT001, in a patient with LOTS, as...
March 13, 2019 13:23 ET | Source: Retrotope

EMA Grants Orphan Medicinal Product Designation for Retrotope’s RT001 in the Treatment of Infantile Neuroaxonal Dystrophy (INAD), a PLA2G6 associated neurodegeneration (PLAN)

LOS ALTOS, Calif., March 13, 2019 (GLOBE NEWSWIRE) -- Retrotope received notification from the Committee for Orphan Medicinal Products of the European Medicines Agency (EMA) that its request for...